By otakuyassine3@gmail.com 
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $16.88.
A number of research analysts recently weighed in on FOLD shares. Bank of America raised their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, October 17th. Jefferies Financial Group assumed coverage on shares of Amicus Therapeutics in a report on Friday, September 6th. They issued a “buy” rating and a $18.00 target price on the stock. StockNews.com lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Cantor Fitzgerald boosted their price objective on Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th.
Read Our Latest Stock Report on Amicus Therapeutics
Amicus Therapeutics Stock Performance
NASDAQ:FOLD opened at $9.63 on Friday. The company has a market cap of $2.88 billion, a price-to-earnings ratio of -28.32 and a beta of 0.60. Amicus Therapeutics has a 1 year low of $9.02 and a 1 year high of $14.57. The stock’s 50 day simple moving average is $10.35 and its two-hundred day simple moving average is $10.59. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42.
Insider Buying and Selling at Amicus Therapeutics
In other news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total transaction of $75,150.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $8,884,273.08. This trade represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 30,401 shares of company stock worth $339,363 over the last 90 days. Company insiders own 2.20% of the company’s stock.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in FOLD. Xponance Inc. boosted its position in Amicus Therapeutics by 5.3% in the 2nd quarter. Xponance Inc. now owns 18,555 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 936 shares during the period. Hazlett Burt & Watson Inc. raised its stake in shares of Amicus Therapeutics by 156.9% during the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 1,569 shares in the last quarter. Arizona State Retirement System boosted its holdings in shares of Amicus Therapeutics by 2.6% in the second quarter. Arizona State Retirement System now owns 62,020 shares of the biopharmaceutical company’s stock valued at $615,000 after purchasing an additional 1,577 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Amicus Therapeutics by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company’s stock valued at $115,000 after purchasing an additional 1,884 shares during the period. Finally, OLD Second National Bank of Aurora bought a new position in Amicus Therapeutics in the third quarter worth approximately $26,000.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Read More
Receive News & Ratings for Amicus Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amicus Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.